December 1, 2025 — Leads & Copy — Agilent Technologies Inc (NYSE: A) has launched new 21 CFR Part 11 compliance software for the Agilent xCELLigence Real-Time Cell Analysis (RTCA) eSight system. The software features a compliance license and enhanced security, enabling deployment in both drug discovery and GMP-regulated settings.
The new software addresses the increasing demand for regulatory-ready digital lab tools in biopharma and cell therapy manufacturing, emphasizing data integrity and audit readiness. Secure user authentication, electronic signatures, and complete audit trails are included in the xCELLigence RTCA eSight, ensuring data trustworthiness and compliance.
The RTCA eSight, with the upgrade, supports regulated environments while maintaining workflow efficiency and data quality. Customers in GMP environments can be assured that their electronic records meet regulatory standards, which streamlines audits and helps with regulatory submissions.
According to Dr. Knut Wintergerst, vice president and general manager of the Cell and Biomolecular Analysis Division at Agilent, the upgrade ensures customers can depend on their data for scientific insights and regulatory compliance. This enhances Agilent’s trustworthiness in discovery and GMP-regulated settings.
Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies. Agilent generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide.
Contact:
To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.
Source: Agilent Technologies Inc
